The FDA cleared Dexcom's Stelo, the first over-the-counter continuous glucose monitor, designed for Type 2 diabetes patients who do not use insulin. The device is scheduled for online release this summer at an 'approachable' cash pay price, and Dexcom shares rose over 2% in extended trading after the announcement.
One outlet so far Only Maldives Republic has reported this among the sources we monitor. A gap in what we monitor, not proof that others did not report it.
Today's clearance expands access to these devices by allowing individuals to purchase a CGM without the involvement of a health care provider.
Nothing to compare yet. If another monitored source reports it, its headline appears beside this one.
addressing the needs of over 25 million Type 2 diabetes patients in the U.S. who do not currently use insulin.
Word for word from the report in Maldives Republic. Open the report
The device boasts a 15-day lifespan before replacement, adding to its appeal for users seeking a convenient and effective monitoring solution.
Word for word from the report in Maldives Republic. Open the report
Shares of Dexcom experienced a positive surge of over 2% in extended trading following the announcement, reflecting the market's confidence in the potential impact of this revolutionary over-the-counter continuous glucose monitor.
Word for word from the report in Maldives Republic. Open the report
Dexcom has received FDA clearance for its innovative over-the-counter continuous glucose monitor, Stelo. This state-of-the-art device, designed specifically for Type 2 diabetes patients who do not use insulin, marks a significant leap forward in accessibility as it is the first glucose biosensor that does not require a prescription.
Word for word from the report in Maldives Republic. Open the report
Scheduled for online release this summer, Stelo offers a simplified and user-friendly experience
Word for word from the report in Maldives Republic. Open the report